文献速递艾滋病与性传播感染

HIV感染者耶氏肺孢子菌肺炎预防方案疗效与安全性的比较:随机对照试验的系统评价与网状Meta分析

Comparative efficacy and safety of Pneumocystis jirovecii pneumonia prophylaxis regimens for people living with HIV: a systematic review and network meta-analysis of randomized controlled trials.
PubMed 文献 · Clin Microbiol Infect · 2024-04-06

该系统评价与网状Meta分析纳入26项随机对照试验、55个治疗臂、7516例HIV感染者,比较耶氏肺孢子菌肺炎预防方案。TMP-SMX在预防PCP上最优,优于氨苯砜方案(RR=0.54;95%CI 0.36-0.83)和雾化喷他脒(RR=0.53;95%CI 0.36-0.77),且是唯一较无治疗/安慰剂有死亡获益的药物(RR=0.79;95%CI 0.64-0.98),但毒性最高。作者结论为TMP-SMX应继续推荐为一线药物,需进一步研究确定最佳剂量。

要点

  • TMP-SMX预防PCP优于氨苯砜方案(RR=0.54;95%CI 0.36-0.83)和雾化喷他脒(RR=0.53;95%CI 0.36-0.77)。
  • TMP-SMX是唯一较无治疗/安慰剂有死亡获益的药物(RR=0.79;95%CI 0.64-0.98)。
  • TMP-SMX停药风险高于氨苯砜方案(RR=1.25;95%CI 1.01-1.54)和雾化喷他脒(RR=7.20;95%CI 5.37-9.66)。

核心结论

  • TMP-SMX是HIV感染者PCP预防最有效的药物,且是唯一有死亡获益的药物。
  • 作者结论认为TMP-SMX应继续被推荐为一线药物。
  • 作者指出需进一步研究确定TMP-SMX最佳剂量以最大化疗效并最小化毒性。

研究设计与样本

  • 系统评价与网状Meta分析,检索Embase、MEDLINE和CENTRAL自建库至2023年6月21日。
  • 纳入比较PCP预防方案的随机对照试验,受试者为HIV感染者,干预为头对头比较或与无治疗/安慰剂比较。
  • 共纳入26项随机对照试验、55个治疗臂、7516例HIV感染者。
  • 采用Cochrane随机对照试验偏倚风险工具2评估偏倚风险,两位独立评价者 duplicate 进行标题或摘要及全文筛选和数据提取。
  • 主要结局为PCP发生率、全因死亡率和因毒性停药,采用网状Meta分析合并并排序,并进行原发与继发预防、年份和剂量的亚组分析。

主要发现

  • TMP-SMX在预防PCP上排名最优,优于氨苯砜方案(RR=0.54;95%CI 0.36-0.83)和雾化喷他脒(RR=0.53;95%CI 0.36-0.77)。
  • TMP-SMX是唯一较无治疗/安慰剂有死亡获益的药物(RR=0.79;95%CI 0.64-0.98)。
  • TMP-SMX因毒性停药风险高于氨苯砜方案(RR=1.25;95%CI 1.01-1.54)和雾化喷他脒(RR=7.20;95%CI 5.37-9.66)。
  • 其他方案之间在PCP预防或死亡率上未检测到显著差异。
  • 亚组分析中结果保持一致。

关键数值与推荐

  • TMP-SMX预防PCP优于氨苯砜方案:RR=0.54;95%CI 0.36-0.83。
  • TMP-SMX预防PCP优于雾化喷他脒:RR=0.53;95%CI 0.36-0.77。
  • TMP-SMX较无治疗/安慰剂有死亡获益:RR=0.79;95%CI 0.64-0.98。
  • TMP-SMX因毒性停药风险高于氨苯砜方案:RR=1.25;95%CI 1.01-1.54。
  • TMP-SMX因毒性停药风险高于雾化喷他脒:RR=7.20;95%CI 5.37-9.66。

临床怎么用

  • 作者结论认为TMP-SMX应继续被推荐为HIV感染者PCP预防的一线药物。
  • 作者指出需进一步研究确定TMP-SMX最佳剂量以最大化疗效并最小化毒性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pneumocystis jirovecii pneumonia (PCP) is a common opportunistic infection among people living with HIV (PWH), particularly among new and untreated cases. Several regimens are available for the prophylaxis of PCP, including trimethoprim-sulfamethoxazole (TMP-SMX), dapsone-based regimens (DBRs), aerosolized pentamidine (AP), and atovaquone. OBJECTIVES: To compare the efficacy and safety of PCP prophylaxis regimens in PWH by network meta-analysis. METHODS: DATA SOURCES: Embase, MEDLINE, and CENTRAL from inception to June 21, 2023. STUDY ELIGIBILITY CRITERIA: Comparative randomized controlled trials (RCTs). PARTICIPANTS: PWH. INTERVENTIONS: Regimens for PCP prophylaxis either compared head-to-head or versus no treatment/placebo. ASSESSMENT OF RISK OF BIAS: Cochrane risk-of-bias tool for RCTs 2. METHODS OF DATA SYNTHESIS: Title or abstract and full-text screening and data extraction were performed in duplicate by two independent reviewers. Data on PCP incidence, all-cause mortality, and discontinuation due to toxicity were pooled and ranked by network meta-analysis. Subgroup analyses of primary versus secondary prophylaxis, by year, and by dosage were performed. RESULTS: A total of 26 RCTs, comprising 55 treatment arms involving 7516 PWH were included. For the prevention of PCP, TMP-SMX was ranked the most favourable agent and was superior to DBRs (risk ratio [RR] = 0.54; 95% CI, 0.36-0.83) and AP (RR = 0.53; 95% CI, 0.36-0.77). TMP-SMX was also the only agent with a mortality benefit compared with no treatment/placebo (RR = 0.79; 95% CI, 0.64-0.98). However, TMP-SMX was also ranked as the most toxic agent with a greater risk of discontinuation than DBRs (RR = 1.25; 95% CI, 1.01-1.54) and AP (7.20; 95% CI, 5.37-9.66). No significant differences in PCP prevention or mortality were detected among the other regimens. The findings remained consistent within subgroups. CONCLUSIONS: TMP-SMX is the most effective agent for PCP prophylaxis in PWH and the only agent to confer a mortality benefit; consequently, it should continue to be recommended as the first-line agent. Further studies are necessary to determine the optimal dosing of TMP-SMX to maximize efficacy and minimize toxicity.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Prosty C, Katergi K, Sorin M, et al. Comparative efficacy and safety of Pneumocystis jirovecii pneumonia prophylaxis regimens for people living with HIV: a systematic review and network meta-analysis of randomized controlled trials. Clin Microbiol Infect. 2024. PMID: 38583518. doi:10.1016/j.cmi.2024.03.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。